Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial

E de Azambuja,Dimitrios Zardavas,Marc Lemort,José Rossari,Camilo Moulin,A. Buttice,V. D'Hondt,Fabienne Lebrun,Yassine Lalami,Fatima Cardoso,Christos Sotiriou,Thierry Gil,Daniel Devriendt,Marianne Paesmans,Martine Piccart-Gebhart,Ahmad Awada

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial

2013

E de Azambuja
Dimitrios Zardavas
Marc Lemort
José Rossari
Camilo Moulin
A. Buttice
V. D'Hondt
Fabienne Lebrun
Yassine Lalami
Fatima Cardoso
Christos Sotiriou
Thierry Gil
Daniel Devriendt
Marianne Paesmans
Martine Piccart-Gebhart
Ahmad Awada

Brain metastases (BMs) pose a clinical challenge in breast cancer (BC). Lapatinib or temozolomide showed activity in BM. Our study assessed the combination of both drugs as treatment for patients with HER2-positive BC and BM.

Keywords:

General surgery
Breast cancer
Temozolomide
Pathology
Progression-free survival
Medicine
Lapatinib
Surrogate endpoint
Metastatic breast cancer
Adverse effect
Regimen
Population
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations